Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease.
作者信息
Chonat Satheesh, Quarmyne Maa-Ohui, Bennett Caroline M, Dean Christina L, Joiner Clinton H, Fasano Ross M, Stowell Sean R
机构信息
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.
出版信息
Haematologica. 2018 Oct;103(10):e483-e485. doi: 10.3324/haematol.2018.194670. Epub 2018 May 24.
Abstract
摘要
相似文献
1
Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease.
Haematologica. 2018 Oct;103(10):e483-e485. doi: 10.3324/haematol.2018.194670. Epub 2018 May 24.
2
Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease.
Transfusion. 2019 Feb;59(2):448-453. doi: 10.1111/trf.15010. Epub 2018 Nov 9.
3
Delayed hemolytic transfusion reaction in sickle cell disease.
Am J Med Sci. 2010 Mar;339(3):266-9. doi: 10.1097/MAJ.0b013e3181c70e14.
4
Treatment of post-transfusion hyperhaemolysis syndrome in Sickle Cell Disease with the anti-IL6R humanised monoclonal antibody Tocilizumab.
Br J Haematol. 2019 Sep;186(6):e212-e214. doi: 10.1111/bjh.16103. Epub 2019 Aug 1.
5
Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.
J Pediatr Hematol Oncol. 2019 Nov;41(8):624-626. doi: 10.1097/MPH.0000000000001307.
6
Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome.
Transfus Apher Sci. 2024 Jun;63(3):103919. doi: 10.1016/j.transci.2024.103919. Epub 2024 Mar 27.
7
Delayed hemolytic transfusion reactions in sickle cell anemia.
South Med J. 1989 Aug;82(8):1034-6. doi: 10.1097/00007611-198908000-00025.
8
Severe neurologic complication after delayed hemolytic transfusion reaction in 2 children with sickle cell anemia: significant diagnosis and therapeutic challenges.
J Pediatr Hematol Oncol. 2008 Dec;30(12):928-30. doi: 10.1097/MPH.0b013e31818c9172.
9
Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
Transfus Clin Biol. 2019 May;26(2):94-98. doi: 10.1016/j.tracli.2019.02.002. Epub 2019 Feb 22.
10
Unexpected Anemia and Reticulocytopenia in an Adolescent With Sickle Cell Anemia Receiving Chronic Transfusion Therapy.
J Pediatr Hematol Oncol. 2015 Oct;37(7):e438-40. doi: 10.1097/MPH.0000000000000410.
引用本文的文献
1
Dynamics of antibody engagement of red blood cells and .
Front Immunol. 2024 Nov 28;15:1475470. doi: 10.3389/fimmu.2024.1475470. eCollection 2024.
2
ABO blood groups and galectins: Implications in transfusion medicine and innate immunity.
Semin Immunol. 2024 Jul-Sep;74-75:101892. doi: 10.1016/j.smim.2024.101892. Epub 2024 Oct 14.
3
Comparison of post-decompressive haematuria in rapid versus gradual bladder decompression in patients with chronic urinary retention.
J West Afr Coll Surg. 2024 Jul-Sep;14(3):249-254. doi: 10.4103/jwas.jwas_5_24. Epub 2024 May 24.
4
Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single-center case series.
Pediatr Blood Cancer. 2024 Aug;71(8):e31061. doi: 10.1002/pbc.31061. Epub 2024 Jun 5.
5
Alloimmunization and hyperhemolysis in sickle cell disease.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):653-659. doi: 10.1182/hematology.2023000499.
6
Future prospects for the clinical transfusion of pig red blood cells.
Blood Rev. 2023 Sep;61:101113. doi: 10.1016/j.blre.2023.101113. Epub 2023 Jul 14.
7
Blood Transfusion Complications and Associated Factors Among Blood-Transfused Adult Patients at Debre Markos Comprehensive Specialized Hospital, Ethiopia: A Cross Sectional Study.
J Blood Med. 2023 Jun 8;14:389-398. doi: 10.2147/JBM.S412002. eCollection 2023.
8
Prior immunization against an intracellular antigen enhances subsequent red blood cell alloimmunization in mice.
Blood. 2023 May 25;141(21):2642-2653. doi: 10.1182/blood.2022016588.
9
The Development and Consequences of Red Blood Cell Alloimmunization.
Annu Rev Pathol. 2023 Jan 24;18:537-564. doi: 10.1146/annurev-pathol-042320-110411. Epub 2022 Nov 9.
10
Evaluation of the Bactericidal Activity of Galectins.
Methods Mol Biol. 2022;2442:517-531. doi: 10.1007/978-1-0716-2055-7_27.
本文引用的文献
1
Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.
Am J Hematol. 2017 Dec;92(12):1340-1348. doi: 10.1002/ajh.24908. Epub 2017 Oct 31.
2
Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
Transfus Clin Biol. 2017 Sep;24(3):227-231. doi: 10.1016/j.tracli.2017.05.016. Epub 2017 Jun 29.
3
Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.
Br J Haematol. 2016 Nov;175(4):744-747. doi: 10.1111/bjh.13884. Epub 2015 Dec 21.
4
Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.
Am J Hematol. 2016 Oct;91(10):989-94. doi: 10.1002/ajh.24460. Epub 2016 Jul 14.
5
Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients.
Blood. 2016 Feb 25;127(8):1062-4. doi: 10.1182/blood-2015-09-669770. Epub 2016 Jan 12.
6
Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion.
Am J Hematol. 2015 Dec;90(12):1135-41. doi: 10.1002/ajh.24188. Epub 2015 Oct 6.
7
Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
Transfusion. 2015 Oct;55(10):2398-403. doi: 10.1111/trf.13144. Epub 2015 May 18.
8
Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience.
Br J Haematol. 2015 Jun;169(5):746-53. doi: 10.1111/bjh.13339. Epub 2015 Mar 5.
9
Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
Transfusion. 2015 Mar;55(3):623-8. doi: 10.1111/trf.12876. Epub 2014 Sep 26.
10
Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease.
Blood. 2014 Jan 16;123(3):377-90. doi: 10.1182/blood-2013-04-495887. Epub 2013 Nov 25.
Zotero 插件